GlassScriptPhysician profile
Lorin D Stein
NPI 1902292261
$4,979.82
in general payments reported to CMS, 2019-2025
20 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,045 · 2022: $714 · 2023: $1,016 · 2024: $1,081 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.88 |
| Education | $134.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $942.09 | 2021-2025 | Cabenuva, Dovato, Rukobia |
| Insmed, INC. | $791.84 | 2021-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $475.36 | 2021-2025 | |
| Melinta Therapeutics, LLC | $469.48 | 2021-2025 | Kimyrsa, Rezzayo, Vabomere |
| Abbvie INC. | $418.89 | 2021-2025 | |
| Astellas Pharma US INC | $403.83 | 2021-2025 | Cresemba |
| Shionogi INC | $300.03 | 2021-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $260.12 | 2021-2025 | Pifeltro, Dificid, Zerbaxa |
| Paratek Pharmaceuticals, INC. | $183.61 | 2021-2025 | Nuzyra |
| Janssen Biotech, INC. | $167.27 | 2021-2023 | Symtuza |
| Ferring Pharmaceuticals INC. | $137.22 | 2023-2025 | Rebyota |
| Theratechnologies INC. | $106.69 | 2021-2023 | Trogarzo, Egrifta |
| Emd Serono, INC. | $90.20 | 2025 | |
| Janssen Products, LP | $65.00 | 2021 | |
| Aimmune Therapeutics, INC. | $50.59 | 2024-2025 | Vowst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $36.20 | 2021 | |
| Pfizer INC. | $23.61 | 2023 | |
| Grifols USA, LLC | $21.70 | 2024 | Xembify |
| La Jolla Pharmaceutical Company | $19.10 | 2024 | Xacduro |
| Nabriva Therapeutics, Plc | $16.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorin Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.